Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Cell therapies offer the promise of treating and altering the course of diseases which cannot be addressed adequately by existing pharmaceuticals. It represents the most recent phase of the biotechnology revolution in medicine. As with many remedies, cell therapies are based on ground-breaking scientific discoveries and technology advancements. Furthermore, cell therapies are a diverse group across cell types and therapeutic indications and have been an active area of research for many years but are now strongly emerging through translation and towards successful commercial development and patient access. Moreover, the next generation of cell therapies now emerging are of diverse class. Cell therapies can be classified by the therapeutic indication they aim to address, e.g. neurological, cardiovascular, ophthalmological; by whether they comprise cells taken from and administered to the same individual (autologous) or derived from a donor (allogeneic); or most commonly by the cell types.
The large number of oncology-oriented cell-based therapy, advancements in technology and products are the factors driving the market growth. In addition, rising government investments in cell-based research is also expected to fuel the growth of cell therapy technology market. However, high cost of cell-based research & low success rate and lack of appropriate & advanced healthcare infrastructure in developing regions are some factors hampering the growth of the market.
The cell therapy technology market is segmented by product, process, cell type, end user and geography
On the basis of product, the cell therapy technology market is segmented into consumables, equipment and systems & software. The equipment segment is further classified into cell processing equipment and single-use equipment. The cell therapy consumables market is driven by the factors such as increasing investments by companies to develop advanced products as well as government initiatives for enhancing cell-based research.
On the basis of process, the cell therapy technology market is bifurcated into cell processing, cell preservation, distribution, & handling and process monitoring & quality control. Especially during culture media processing, the cell processing stage makes the highest use of cell therapy instruments and media. Hence, the cell processing segment is on high demand.
The cell types studied in this report are human cells and animal cells. The human cells segment is further classified into Stem Cells and differentiated Cells. In the last few years, stem cells therapy has been gaining traction worldwide. A significant rise in the number of clinical application of stem cells and the advent of new treatments for chronic diseases are estimated to enhance the growth of the stem cells segment in near future.
The end user of the cell therapy technology market is segmented into life science research companies and research institutes. The large share of life science research companies segment can be attributed to the high adoption of advanced instruments in cell-based experiments and cancer research as well as the increasing number of research & development facilities globally.
Geographically, the global cell therapy technology market is diversified into North America, Europe, Asia-Pacific and rest of the world. The North America region dominated the cell therapy technology market in the 2018, owing to increasing R&D activities in the pharmaceutical and biotechnology industries in these region and high prevalence of chronic diseases. However, Asia Pacific is projected to emerge as the most promising region during the forecast period, due to the increasing research funding for vaccine development.
The key companies operating in the market are Thermo Fisher Scientific, Inc., Merck KGaA, Terumo Bct, Inc. (A Subsidiary of Terumo Corporation), Lonza Group, Ge Healthcare, Sartorius, Becton, Dickinson and Company, Beckman Coulter, Inc. (Subsidiary of Danaher Corporation), Miltenyi Biotec GmbH and Stemcell Technologies. New product launches, mergers & acquisitions are the key strategies adopted by market players to ensure their growth in the market.
The cell therapy technology market is segmented by product, process, cell type, end user and geography. On the basis of product, the cell therapy technology market is segmented into consumables, equipment and systems & software. The equipment segment is further classified into cell processing equipment and single-use equipment. The cell therapy consumables market is driven by the factors such as increasing investments by companies to develop advanced products as well as government initiatives for enhancing cell-based research.
Based on the process, the market is bifurcated into cell processing, cell preservation, distribution, & handling and process monitoring & quality control. Especially during culture media processing, the cell processing stage makes the highest use of cell therapy instruments and media. Hence, the cell processing segment is on high demand.
The cell types studied are human cells and animal cells. In the last few years, stem cells therapy has been gaining traction worldwide. A significant rise in the number of clinical application of stem cells and the advent of new treatments for chronic diseases are estimated to enhance the growth of the stem cells segment in near future.
By end user, the cell therapy technology market is bifurcated into life science research companies and research institutes. The large share of life science research companies segment can be attributed to the high adoption of advanced instruments in cell-based experiments and cancer research as well as the increasing number of research & development facilities globally.
Geographically, the global cell therapy technology market is diversified into North America, Europe, Asia-Pacific and rest of the world. The North America region dominated the cell therapy technology market in the 2018, owing to increasing R&D activities in the pharmaceutical and biotechnology industries in these region and high prevalence of chronic diseases. However, Asia Pacific is projected to emerge as the most promising region during the forecast period, due to the increasing research funding for vaccine development.
Why to buy this report:
